WO2006016276A3 - Procédés thérapeutiques et de diagnostic et compositions ciblant la protéine 4ig-b7-h3 et son récepteur contrepartie présent sur les cellules nk - Google Patents

Procédés thérapeutiques et de diagnostic et compositions ciblant la protéine 4ig-b7-h3 et son récepteur contrepartie présent sur les cellules nk Download PDF

Info

Publication number
WO2006016276A3
WO2006016276A3 PCT/IB2005/002688 IB2005002688W WO2006016276A3 WO 2006016276 A3 WO2006016276 A3 WO 2006016276A3 IB 2005002688 W IB2005002688 W IB 2005002688W WO 2006016276 A3 WO2006016276 A3 WO 2006016276A3
Authority
WO
WIPO (PCT)
Prior art keywords
counterpart
therapeutic
protein
cell receptor
diagnostic methods
Prior art date
Application number
PCT/IB2005/002688
Other languages
English (en)
Other versions
WO2006016276A2 (fr
Inventor
Alessandro Moretta
Roberta Castriconi
Christina Bottino
Lorenzo Moretta
Original Assignee
Innate Pharma Sa
Univ Genova
Alessandro Moretta
Roberta Castriconi
Christina Bottino
Lorenzo Moretta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05775603.3T priority Critical patent/DK1773884T3/da
Priority to JP2007524425A priority patent/JP5130044B2/ja
Priority to US11/659,175 priority patent/US7732131B2/en
Priority to AT05775603T priority patent/ATE548389T1/de
Priority to AU2005270918A priority patent/AU2005270918B2/en
Priority to CA2575607A priority patent/CA2575607C/fr
Application filed by Innate Pharma Sa, Univ Genova, Alessandro Moretta, Roberta Castriconi, Christina Bottino, Lorenzo Moretta filed Critical Innate Pharma Sa
Priority to EP05775603A priority patent/EP1773884B1/fr
Priority to ES05775603T priority patent/ES2381557T3/es
Publication of WO2006016276A2 publication Critical patent/WO2006016276A2/fr
Publication of WO2006016276A3 publication Critical patent/WO2006016276A3/fr
Priority to US12/775,531 priority patent/US8465931B2/en
Priority to US13/912,333 priority patent/US20130315892A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'identification de la protéine 4Ig-B7-H3 en tant que molécule associée à une tumeur qui empêche la lyse médiée par les cellules NK via un récepteur de la 4Ig-B7-H3 présent sur les cellules NK. L'invention concerne des composés qui interfèrent avec les interactions entre la protéine 4Ig-B7-H3 et son récepteur qu'on peut utiliser pour rendre la cytotoxicité des cellules NK possible. L'invention concerne également des composés qui se lient aux cellules exprimant la 4Ig-B7-H3 de façon à les inhiber ou à les éliminer. Les composés sont particulièrement utiles dans le traitement de tumeurs, d'affections inflammatoires, d'infections et de transplantations. L'invention concerne également des procédés servant à diagnostiquer une maladie en détectant une protéine 4Ig-B7-H3.
PCT/IB2005/002688 2004-08-03 2005-08-02 Procédés thérapeutiques et de diagnostic et compositions ciblant la protéine 4ig-b7-h3 et son récepteur contrepartie présent sur les cellules nk WO2006016276A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2007524425A JP5130044B2 (ja) 2004-08-03 2005-08-02 ４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物
US11/659,175 US7732131B2 (en) 2004-08-03 2005-08-02 Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
AT05775603T ATE548389T1 (de) 2004-08-03 2005-08-02 Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
AU2005270918A AU2005270918B2 (en) 2004-08-03 2005-08-02 Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
CA2575607A CA2575607C (fr) 2004-08-03 2005-08-02 Procedes therapeutiques et de diagnostic et compositions ciblant la proteine 4ig-b7-h3 et son recepteur contrepartie present sur les cellules nk
DK05775603.3T DK1773884T3 (da) 2004-08-03 2005-08-02 Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
EP05775603A EP1773884B1 (fr) 2004-08-03 2005-08-02 Procedes therapeutiques et de diagnostic et compositions ciblant la proteine 4ig-b7-h3 et son recepteur contrepartie present sur les cellules nk
ES05775603T ES2381557T3 (es) 2004-08-03 2005-08-02 Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
US12/775,531 US8465931B2 (en) 2004-08-03 2010-05-07 Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US13/912,333 US20130315892A1 (en) 2004-08-03 2013-06-07 Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59872704P 2004-08-03 2004-08-03
US60/598,727 2004-08-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/659,175 A-371-Of-International US7732131B2 (en) 2004-08-03 2005-08-02 Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US12/775,531 Division US8465931B2 (en) 2004-08-03 2010-05-07 Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor

Publications (2)

Publication Number Publication Date
WO2006016276A2 WO2006016276A2 (fr) 2006-02-16
WO2006016276A3 true WO2006016276A3 (fr) 2006-05-04

Family

ID=35241619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002688 WO2006016276A2 (fr) 2004-08-03 2005-08-02 Procédés thérapeutiques et de diagnostic et compositions ciblant la protéine 4ig-b7-h3 et son récepteur contrepartie présent sur les cellules nk

Country Status (9)

Country Link
US (3) US7732131B2 (fr)
EP (2) EP1773884B1 (fr)
JP (2) JP5130044B2 (fr)
AT (1) ATE548389T1 (fr)
AU (1) AU2005270918B2 (fr)
CA (1) CA2575607C (fr)
DK (2) DK2412728T3 (fr)
ES (2) ES2534288T3 (fr)
WO (1) WO2006016276A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2094307A4 (fr) * 2006-11-08 2015-08-26 Macrogenics West Inc Tes7, et anticorps se liant à celui-ci
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008100934A1 (fr) * 2007-02-14 2008-08-21 Mayo Foundation For Medical Education And Research Molécule b7-h3 pour lutter contre le cancer
WO2009129333A1 (fr) * 2008-04-15 2009-10-22 Oxigene, Inc. Procédés pour améliorer l'efficacité d'agents de détérioration vasculaire
FR2937470B1 (fr) 2008-10-16 2010-12-10 Fibercryst Systeme amplificateur optique pour laser impulsionnel a base d'un milieu a gain guidant et laser impulisionnel le comprenant
EP2399130A4 (fr) * 2009-02-20 2012-06-06 Wayne John Cancer Inst Dosage du b7-h3 par billes couplées à un anticorps pour l'isolement et la détection de cellules tumorales circulantes dans des fluides corporels de patientes atteints d'un mélanome et d'un cancer du sein
EP2473523A2 (fr) 2009-08-31 2012-07-11 Amplimmune, Inc. Méthodes et compositions permettant d'inhiber les rejets de greffe
AU2010315084A1 (en) 2009-11-06 2012-05-31 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive diagnosis of graft rejection in organ transplant patients
WO2012004410A1 (fr) * 2010-07-09 2012-01-12 Oslo Universitetssykehus Hf Antagonistes de b7-h3 et taxanes
LT2703486T (lt) * 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
WO2015123241A1 (fr) * 2014-02-14 2015-08-20 Chi Andrew S Procédés améliorés pour le traitement de cancers liés à la vascularisation
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6944925B2 (ja) 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
WO2017062619A2 (fr) 2015-10-08 2017-04-13 Macrogenics, Inc. Polythérapie pour le traitement du cancer
EP3432934B1 (fr) 2016-03-24 2022-02-23 Bayer Pharma Aktiengesellschaft Promedicaments d'agents actifs cytotoxiques comprenant des groupes clivables par enzymes
JP7002467B2 (ja) 2016-04-15 2022-01-20 マクロジェニクス，インコーポレーテッド 新規のｂ７‐ｈ３結合分子、その抗体薬物コンジュゲート、及びその使用方法
EP3919518A1 (fr) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
CA3037851A1 (fr) 2016-10-21 2018-04-26 Innate Pharma Traitement avec des agents anti-kir3dl2
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
TW202124717A (zh) * 2019-12-30 2021-07-01 白素梅 人4IgB7-H3的突變編碼基因及其調節免疫的應用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018204A1 (fr) * 1999-09-03 2001-03-15 Curagen Corporation Polynucleotides codant des membres de la famille humaine d'antigenes b7 d'activation des lymphocytes b et polypeptides ainsi codes
WO2001094413A2 (fr) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR401702A (fr) 1908-08-04 1909-09-13 Charles Marenghi Et Cie Soc Dispositif permettant d'imiter mécaniquement la mandoline
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
PT954588E (pt) 1996-12-20 2007-03-30 Amgen Inc Composições que contêm uma proteína de fusão ob e métodos para a sua preparação e utilização
WO1998034957A1 (fr) 1997-02-11 1998-08-13 Immunomedics, Inc. Stimulation d'une reponse immunitaire par anticorps marques avec l'epitope d'alpha-galactosyle
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
JPH11279009A (ja) 1998-03-26 1999-10-12 Sumitomo Chem Co Ltd 除草剤組成物
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU5812199A (en) 1998-09-08 2000-03-27 E.I. Du Pont De Nemours And Company Plant farnesyltransferases
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
MXPA01011845A (es) 1999-05-19 2002-06-21 Lexigen Pharm Corp Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc.
EP1514933A1 (fr) 1999-07-08 2005-03-16 Research Association for Biotechnology Protéine sécrétoire ou protéine de membrane
AU783899B2 (en) 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
FR2804027B1 (fr) 2000-01-20 2002-08-30 Monoclonal Antibodies Therapeu Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2423843A1 (fr) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps monoclonal 8h9
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
EP1343822B1 (fr) 2000-12-18 2012-05-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux moyens destines au diagnostic et la therapie de ctcl
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
EP1369128A1 (fr) 2002-06-07 2003-12-10 Procorde GmbH Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique
MXPA04012664A (es) 2002-06-19 2005-08-15 Raven Biotechnologies Inc Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo.
AU2004258747B2 (en) 2003-07-24 2009-11-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018204A1 (fr) * 1999-09-03 2001-03-15 Curagen Corporation Polynucleotides codant des membres de la famille humaine d'antigenes b7 d'activation des lymphocytes b et polypeptides ainsi codes
WO2001094413A2 (fr) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASTRICONI ROBERTA ET AL: "Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 24 AUG 2004, vol. 101, no. 34, 24 August 2004 (2004-08-24), pages 12640 - 12645, XP002354541, ISSN: 0027-8424 *
CHAPOVAL I ET AL: "B7-H3: a costimulatory molecule for T cell activation and IFN-g production", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 2, no. 3, March 2001 (2001-03-01), pages 269 - 274, XP002958730, ISSN: 1529-2908 *
STEINBERGER PETER ET AL: "Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 FEB 2004, vol. 172, no. 4, 15 February 2004 (2004-02-15), pages 2352 - 2359, XP002354540, ISSN: 0022-1767 *
SUN M ET AL: "Characterization of mouse and human B7-H3 genes", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 168, 2002, pages 6294 - 6297, XP002313221, ISSN: 0022-1767 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
CA2575607A1 (fr) 2006-02-16
CA2575607C (fr) 2017-07-11
EP1773884A2 (fr) 2007-04-18
WO2006016276A2 (fr) 2006-02-16
US20100285531A1 (en) 2010-11-11
JP2012197311A (ja) 2012-10-18
DK1773884T3 (da) 2012-05-21
AU2005270918B2 (en) 2011-03-03
EP2412728B1 (fr) 2015-01-07
EP1773884B1 (fr) 2012-03-07
JP5130044B2 (ja) 2013-01-30
JP5560301B2 (ja) 2014-07-23
DK2412728T3 (en) 2015-04-07
ES2381557T3 (es) 2012-05-29
US20130315892A1 (en) 2013-11-28
AU2005270918A1 (en) 2006-02-16
EP2412728A3 (fr) 2012-05-02
ES2534288T3 (es) 2015-04-21
US20080081346A1 (en) 2008-04-03
US8465931B2 (en) 2013-06-18
US7732131B2 (en) 2010-06-08
JP2008509130A (ja) 2008-03-27
ATE548389T1 (de) 2012-03-15
EP2412728A2 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
WO2006016276A3 (fr) Procédés thérapeutiques et de diagnostic et compositions ciblant la protéine 4ig-b7-h3 et son récepteur contrepartie présent sur les cellules nk
WO2009015284A3 (fr) Protéines de liaison à un antigène de récepteur d'il-18
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
CA2796722C (fr) Compositions et procedes permettant l'administration selective de molecules d'oligonucleotides a des types de neurones specifiques
WO2010078421A8 (fr) Composés de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amines substituées
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
EP3064220A3 (fr) Compositions et procédés pour le traitement d'infections et de tumeurs
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2007073499A3 (fr) Molecules epha2 bite et leur utilisation
WO2009012109A3 (fr) Composes contenant de la cyanine utiles dans l'imagerie et le traitement du cancer
WO2013158644A3 (fr) Agents thérapeutiques ciblés
WO2006125962A3 (fr) Recepteurs des lymphocytes t se fixant specifiquement a vygfvracl-hla-a24
WO2010081001A3 (fr) Fusions de gène récurrent dans le cancer
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
WO2006113909A3 (fr) Agents de liaison anti-cd70 humanises et utilisations
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
WO2011082266A3 (fr) Composés hétérocycliques substitués
WO2009094148A3 (fr) Anticorps ron et leurs utilisations
WO2008033987A3 (fr) Compositions et procédés de prévention du cancer avec des cupredoxines
WO2011034906A3 (fr) Fusions de gène récurrentes dans le cancer de la prostate
WO2009082038A3 (fr) Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
WO2007028154A3 (fr) Medicaments arsenicaux encapsules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2575607

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11659175

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005270918

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007524425

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005775603

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005270918

Country of ref document: AU

Date of ref document: 20050802

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005270918

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775603

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11659175

Country of ref document: US